Skip to search formSkip to main contentSkip to account menu

grazoprevir

Known as: (1aR,5S,8S,10R,22aR)-5-tert-butyl-N-{(1R,2S)-1-[(cyclopropanesulfonyl)carbamoyl]-2-ethenylcyclopropyl}-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxamide 
National Institutes of Health

Related topics

Related topics

6 relations
Breast Cancer Resistance Protein Inhibitors [MoA]HCV NS3/4A Protease Inhibitors [MoA]Hepatitis Celbasvir / grazoprevir

Broader (1)

MK-5172

Narrower (1)

Zepatier

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Elbasvir/Grazoprevir in People With Hepatitis C Genotype 1 Infection and Child-Pugh Class B Cirrhosis: The C-SALT Study
INTRODUCTION: Treatment options are limited for people infected with hepatitis C virus (HCV) with decompensated liver disease… 
Review
2019
Review
2019
Outcomes of heart transplantation from hepatitis C virus-positive donors.
2019
2019
HCV genotype 1-6 NS3 residue 80 substitutions impact protease inhibitor activity and promote viral escape.
2019
2019
Patient-reported symptoms during and after direct acting antiviral therapies for chronic hepatitis C: The PROP UP Study.
Review
2018
Review
2018
Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C VirusInfected Donors to Noninfected Recipients
More than 420000 persons in the United States require hemodialysis for end-stage kidney disease (1). These patients face a high… 
2018
2018
The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection
AbstractBackground Genotype 1b (GT1b) is the most common subtype of the hepatitis C virus (HCV). We present an integrated… 
Highly Cited
2017
Highly Cited
2017
Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis.
BACKGROUND & AIMS Persons with hepatitis C virus (HCV) infection are at risk of progressive liver disease, cirrhosis, and… 
Highly Cited
2017
Highly Cited
2017
Short‐duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: A randomized trial
Direct‐acting antiviral agents (DAAs) represent the standard of care for patients with hepatitis C virus (HCV) infection… 
Review
2016
Review
2016
Systematic review: current concepts and challenges for the direct‐acting antiviral era in hepatitis C cirrhosis
The burden of HCV cirrhosis is high and projected to increase significantly over the next decade. While interferon therapy is… 
Review
2015
Review
2015
GrazoprevirElbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection
Context Various oral interferon- and ribavirin-free regimens are becoming available to treat chronic hepatitis C virus (HCV… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)